• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

希腊重症监护病房耐碳青霉烯类 versus 碳青霉烯类敏感鲍曼不动杆菌菌血症:危险因素、临床特征和结局。

Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes.

机构信息

1st Department of Intensive Care, Evangelismos Hospital, University of Athens Medical School, 45-47 Ipsilantou Str., 106 76, Athens, Greece.

出版信息

Infection. 2010 Jun;38(3):173-80. doi: 10.1007/s15010-010-0008-1. Epub 2010 Mar 12.

DOI:10.1007/s15010-010-0008-1
PMID:20224962
Abstract

BACKGROUND

There has been an increasing incidence of carbapenem-resistant Acinetobacter baumannii (CRAB) infections in recent years. The objective of this study was to determine specific risk factors for and outcome of bacteremia due to CRAB isolates among our ICU patients with A. baumannii bacteremia.

PATIENTS AND METHODS

Among 96 patients with ICU-acquired A. baumannii bacteremia, 30 patients with CRAB were compared with the remaining 66 with carbapenem-susceptible A. baumannii (CSAB) isolates.

RESULTS

Recent ventilator-associated pneumonia (VAP) due to CRAB (OR 16.74, 95% CI 3.16-88.79, p = 0.001) and a greater number of intravascular devices (OR 3.93, 95% CI 1.9-13.0, p = 0.025) were independently associated with CRAB bacteremia acquisition. Patients with CRAB bacteremia had a lower severity of illness on admission than those with CSAB. Although, by univariate analysis, patients with CRAB were more likely to have had exposure to colistin, carbapenems and linezolid, multivariate analysis did not revealed any significant association. The mortality was not different between patients with CRAB and CSAB bacteremia (43.3 vs. 46.9%, p = 0.740). Severity of organ failure (OR 1.42, 95% CI 1.20-1.67, p = 0.001), and increased white blood cell (WBC) count (OR 1.09, 95% CI 1.01-1.19, p = 0.036), at bacteremia onset were independently associated with mortality.

CONCLUSION

VAP due to CRAB and excess use of intravascular devices are the most important risk factors for CRAB bacteremia in our ICU. Severity of organ failure and WBC count at A. baumannii bacteremia onset are independently associated with mortality.

摘要

背景

近年来,碳青霉烯类耐药鲍曼不动杆菌(CRAB)感染的发病率不断上升。本研究的目的是确定我们 ICU 中患有鲍曼不动杆菌菌血症的患者中 CRAB 分离株菌血症的特定危险因素和结果。

患者和方法

在 96 例 ICU 获得性鲍曼不动杆菌菌血症患者中,将 30 例 CRAB 患者与其余 66 例碳青霉烯类敏感鲍曼不动杆菌(CSAB)分离株患者进行比较。

结果

最近因 CRAB 引起的呼吸机相关性肺炎(VAP)(比值比 [OR] 16.74,95%置信区间 [CI] 3.16-88.79,p = 0.001)和更多的血管内装置(OR 3.93,95% CI 1.9-13.0,p = 0.025)与 CRAB 菌血症的获得独立相关。与 CSAB 菌血症患者相比,CRAB 菌血症患者入院时疾病严重程度较低。尽管单变量分析显示,CRAB 患者更有可能接触过黏菌素、碳青霉烯类和利奈唑胺,但多变量分析并未发现任何显著关联。CRAB 和 CSAB 菌血症患者的死亡率无差异(43.3% vs. 46.9%,p = 0.740)。器官衰竭的严重程度(OR 1.42,95% CI 1.20-1.67,p = 0.001)和白细胞计数(WBC)升高(OR 1.09,95% CI 1.01-1.19,p = 0.036)在菌血症发生时与死亡率独立相关。

结论

CRAB 引起的 VAP 和血管内装置的过度使用是我们 ICU 中 CRAB 菌血症的最重要危险因素。器官衰竭的严重程度和 WBC 计数在鲍曼不动杆菌菌血症发病时与死亡率独立相关。

相似文献

1
Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes.希腊重症监护病房耐碳青霉烯类 versus 碳青霉烯类敏感鲍曼不动杆菌菌血症:危险因素、临床特征和结局。
Infection. 2010 Jun;38(3):173-80. doi: 10.1007/s15010-010-0008-1. Epub 2010 Mar 12.
2
Prospective multi-center evaluation on risk factors, clinical characteristics and outcomes due to carbapenem resistance in complex bacteraemia: experience from the Chinese Antimicrobial Resistance Surveillance of Nosocomial Infections (CARES) Network.复杂血流感染碳青霉烯耐药的危险因素、临床特征和结局的前瞻性多中心评估:来自中国医院感染抗菌药物耐药监测网(CARES)的经验。
J Med Microbiol. 2020 Jul;69(7):949-959. doi: 10.1099/jmm.0.001222.
3
Risk factors and outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia in the neonate: A case-case-control study.新生儿耐碳青霉烯类鲍曼不动杆菌呼吸机相关性肺炎的危险因素及结局:一项病例-病例对照研究。
J Infect Chemother. 2016 Jul;22(7):444-9. doi: 10.1016/j.jiac.2016.03.013. Epub 2016 May 24.
4
Insights into the epidemiology, risk factors, and clinical outcomes of carbapenem-resistant infections in critically ill children.重症儿童耐碳青霉烯类感染的流行病学、危险因素和临床结局的研究进展。
Front Public Health. 2023 Nov 30;11:1282413. doi: 10.3389/fpubh.2023.1282413. eCollection 2023.
5
Adaptations of carbapenem resistant (CRAB) in the hospital environment causing sustained outbreak.耐碳青霉烯类肠杆菌科细菌(CRAB)在医院环境中的适应性导致持续暴发。
J Med Microbiol. 2021 Mar;70(3). doi: 10.1099/jmm.0.001345. Epub 2021 Mar 19.
6
Risk factors for occurrence and 30-day mortality for carbapenem-resistant Acinetobacter baumannii bacteremia in an intensive care unit.重症监护病房耐碳青霉烯类鲍曼不动杆菌菌血症发生和 30 天死亡率的危险因素。
J Korean Med Sci. 2012 Aug;27(8):939-47. doi: 10.3346/jkms.2012.27.8.939. Epub 2012 Jul 25.
7
Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia.碳青霉烯类耐药鲍曼不动杆菌菌血症患者的危险因素和临床结局。
J Microbiol Immunol Infect. 2012 Oct;45(5):356-62. doi: 10.1016/j.jmii.2011.12.009. Epub 2012 May 9.
8
[Risk factors and resistance patterns of invasive infection in Children].[儿童侵袭性感染的危险因素及耐药模式]
Zhonghua Er Ke Za Zhi. 2022 Aug 2;60(8):762-768. doi: 10.3760/cma.j.cn112140-20220502-00404.
9
Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections.碳青霉烯类耐药和接受积极抗菌治疗对鲍曼不动杆菌血流感染临床结局的影响。
Antimicrob Agents Chemother. 2011 Oct;55(10):4844-9. doi: 10.1128/AAC.01728-10. Epub 2011 Aug 8.
10
Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii.重症肺炎合并耐碳青霉烯鲍曼不动杆菌感染患者的抗生素策略及临床转归
Clin Microbiol Infect. 2018 Aug;24(8):908.e1-908.e7. doi: 10.1016/j.cmi.2017.10.033. Epub 2017 Nov 3.

引用本文的文献

1
Prevalence, Risk Factors, and Outcome of Carbapenem-resistant Infections in a Community Hospital in Madinah, Saudi Arabia.沙特阿拉伯麦地那一家社区医院耐碳青霉烯类感染的患病率、危险因素及结局
Saudi J Med Med Sci. 2024 Oct-Dec;12(4):306-313. doi: 10.4103/sjmms.sjmms_582_23. Epub 2024 Oct 12.
2
Nosocomial, Healthcare-Associated, and Community-Acquired in China: Clinical Characteristics, Antimicrobial Resistance Patterns and Risk Factors Associated with Carbapenem Resistance.中国的医院获得性、医疗保健相关和社区获得性感染:临床特征、抗菌药物耐药模式及与碳青霉烯类耐药相关的危险因素
Infect Drug Resist. 2024 Sep 19;17:4089-4099. doi: 10.2147/IDR.S469244. eCollection 2024.
3

本文引用的文献

1
Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe.欧洲广泛耐药和泛耐药革兰氏阴性杆菌的出现。
Euro Surveill. 2008 Nov 20;13(47):19045.
2
Mortality rates associated with multidrug-resistant Acinetobacter baumannii infection in surgical intensive care units.外科重症监护病房中与多重耐药鲍曼不动杆菌感染相关的死亡率
Infect Control Hosp Epidemiol. 2008 Nov;29(11):1080-3. doi: 10.1086/591456.
3
Risk factors for and influence of bloodstream infections on mortality: a 1-year prospective study in a Greek intensive-care unit.
Acinetobacter spp. bloodstream infection in hematological patients: a 10-year single-center study.
血液系统疾病患者感染不动杆菌属:一项为期 10 年的单中心研究。
BMC Infect Dis. 2023 Nov 14;23(1):796. doi: 10.1186/s12879-023-08789-6.
4
Antimicrobial peptide 2K4L disrupts the membrane of multidrug-resistant and protects mice against sepsis.抗菌肽2K4L破坏多重耐药菌的细胞膜并保护小鼠免受败血症侵害。
Front Microbiol. 2023 Oct 24;14:1258469. doi: 10.3389/fmicb.2023.1258469. eCollection 2023.
5
Case Report: Molecular Characterization of Bloodstream Infections due to Carbapenem-Resistant Acinetobacter baumannii: A Pediatric Case Series.病例报告:耐碳青霉烯鲍曼不动杆菌血流感染的分子特征:一项儿科病例系列研究。
Am J Trop Med Hyg. 2023 Nov 6;109(6):1270-1273. doi: 10.4269/ajtmh.23-0142. Print 2023 Dec 6.
6
Bloodstream Infections: A Nationwide Study in Israel.血流感染:以色列的一项全国性研究
Microorganisms. 2023 Aug 29;11(9):2178. doi: 10.3390/microorganisms11092178.
7
The significant role of Carbapenems-resistant in mortality rate of patients with COVID-19.碳青霉烯类耐药在新型冠状病毒肺炎患者死亡率中的重要作用。
Vacunas. 2023 Jan-Mar;24(1):13-18. doi: 10.1016/j.vacun.2022.10.004. Epub 2022 Nov 1.
8
Multicenter Study of the Risk Factors and Outcomes of Bloodstream Infections Caused by Carbapenem-Non-Susceptible in Indonesia.印度尼西亚耐碳青霉烯类血流感染的危险因素及转归的多中心研究。
Trop Med Infect Dis. 2022 Jul 31;7(8):161. doi: 10.3390/tropicalmed7080161.
9
Adverse clinical outcomes associated with carbapenem-resistant (CRA) infections: a systematic review and meta-analysis.与耐碳青霉烯类(CRA)感染相关的不良临床结局:一项系统评价和荟萃分析。
JAC Antimicrob Resist. 2021 Nov 5;3(4):dlab157. doi: 10.1093/jacamr/dlab157. eCollection 2021 Dec.
10
The role of antimicrobial resistance on long-term mortality and quality of life in critically ill patients: a prospective longitudinal 2-year study.抗菌药物耐药性对危重症患者长期死亡率和生活质量的影响:一项前瞻性纵向 2 年研究。
Health Qual Life Outcomes. 2021 Mar 3;19(1):72. doi: 10.1186/s12955-021-01712-0.
血流感染的危险因素及其对死亡率的影响:在希腊一家重症监护病房进行的为期1年的前瞻性研究。
Epidemiol Infect. 2009 May;137(5):727-35. doi: 10.1017/S0950268808001271. Epub 2008 Sep 16.
4
Acinetobacter baumannii: a universal threat to public health?鲍曼不动杆菌:对公众健康的普遍威胁?
Int J Antimicrob Agents. 2008 Aug;32(2):106-19. doi: 10.1016/j.ijantimicag.2008.02.013. Epub 2008 Jun 20.
5
Risk factors of multidrug resistance in nosocomial bacteremia due to Acinetobacter baumannii: a case-control study.鲍曼不动杆菌所致医院获得性菌血症多重耐药的危险因素:一项病例对照研究。
J Microbiol Immunol Infect. 2008 Apr;41(2):118-23.
6
Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options.鲍曼不动杆菌:流行病学、抗菌药物耐药性及治疗选择
Clin Infect Dis. 2008 Apr 15;46(8):1254-63. doi: 10.1086/529198.
7
Acinetobacter baumannii infections in a surgical intensive care unit: predictors of multi-drug resistance.外科重症监护病房中的鲍曼不动杆菌感染:多重耐药的预测因素
World J Surg. 2008 Jun;32(6):1194-202. doi: 10.1007/s00268-008-9571-3.
8
Acinetobacter infection.不动杆菌感染
N Engl J Med. 2008 Mar 20;358(12):1271-81. doi: 10.1056/NEJMra070741.
9
Exposure to quinolones is associated with carbapenem resistance among colistin-susceptible Acinetobacter baumannii blood isolates.在对黏菌素敏感的鲍曼不动杆菌血液分离株中,喹诺酮类药物暴露与碳青霉烯类耐药相关。
Int J Antimicrob Agents. 2007 Nov;30(5):409-14. doi: 10.1016/j.ijantimicag.2007.06.026. Epub 2007 Sep 11.
10
Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes.多重耐药鲍曼不动杆菌对临床结局的影响。
Eur J Clin Microbiol Infect Dis. 2007 Nov;26(11):793-800. doi: 10.1007/s10096-007-0371-8.